Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
5(21%)
Results Posted
13%(1 trials)

Phase Distribution

Ph phase_2
1
4%
Ph not_applicable
7
29%
Ph phase_4
1
4%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
1(11.1%)
Phase 4Post-market surveillance
1(11.1%)
N/ANon-phased studies
7(77.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

5

trials recruiting

Total Trials

24

all time

Status Distribution
Active(8)
Completed(8)
Terminated(2)
Other(6)

Detailed Status

Completed8
unknown6
Recruiting5
Not yet recruiting3
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
24
Active
5
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (11.1%)
Phase 41 (11.1%)
N/A7 (77.8%)

Trials by Status

withdrawn28%
unknown625%
completed833%
not_yet_recruiting313%
recruiting521%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT06694363

New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome

Recruiting
NCT07337707Not Applicable

New Microbiota-endocrine Axis in Fructose Malabsorption-caused Visceral Hypersensitivity in Irritable Bowel Syndrome.

Not Yet Recruiting
NCT04301401Not Applicable

Assessment of Changes in Vaginal Microbiota Profiles Before and After Vaginal Urogynecologic Surgery

Completed
NCT07280091

Study of Skin and Gut Microbiome in a Skin Condition Involving Skin Barrier Impairment and Allergic Symptoms: Netherton Syndrome

Not Yet Recruiting
NCT02317133

Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura

Completed
NCT07078435Not Applicable

Innate Immunity, MIcrobiota and Inovative Treatments in Endometriosis

Not Yet Recruiting
NCT06451913Phase 4

Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))

Recruiting
NCT07118137

Memory Deterioration in Alzheimer Disease

Recruiting
NCT06235411Not Applicable

Psilocybin in Alcohol Use Disorder With Comorbid Depression

Completed
NCT06161896

Characterization and Clinical Impact of the Gut Microbiota in Lymphoma

Recruiting
NCT05532865

Prospective Cohort of Patients With Systemic Sclerosis at Brest University Hospital With Biobanking

Recruiting
NCT02784821Phase 2

Antibiotic "Dysbiosis" in Preterm Infants

Completed
NCT02813590

Ascitic Fluid Microbiome in Liver Cirrhosis

Withdrawn
NCT05543590Not Applicable

Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID

Withdrawn
NCT03359642Not Applicable

Characterization of the Intestinal Microbiota in Patients With Inflammatory Bowel Disease and/or Spondyloarthritis and Study of the Impact of an Anti-TNF Alpha Therapy

Completed
NCT04272307

MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.

Unknown
NCT03470506

A Study of the Relationship of Gut Microbial Composition and Stroke Outcome

Unknown
NCT03581201

The Relationship of the Intestinal Microbiome and the Menstrual Cycle

Unknown
NCT03800147Not Applicable

Effects of Nutritional Fat on the Growth of Intestinal E. Coli

Unknown
NCT03494101

Interaction Between Non-typhoid Salmonella, Host Microbiota, and Immune System During Acute Infection and Remission

Unknown

Drug Details

Intervention Type
OTHER
Total Trials
24